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Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of
Na/H exchanger NHE3 by glucagon-like peptide 1 receptor agonist
exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol
297: F1647–F1655, 2009. First published September 23, 2009;
doi:10.1152/ajprenal.00082.2009.—The gut incretin hormone gluca-
gon-like peptide 1 (GLP-1) is released in response to ingested nutri-
ents and enhances insulin secretion. In addition to its insulinotropic
properties, GLP-1 has been shown to have natriuretic actions paral-
leled by a diminished proton secretion. We therefore studied the role
of the GLP-1 receptor agonist exendin-4 in modulating the activity of
Na/H exchanger NHE3 in LLC-PK1 cells. We found that NHE3-
mediated Na-dependent intracellular pH (pHi) recovery decreased
50% after 30-min treatment with 1 nM exendin-4. Pharmacological
inhibitors and cAMP analogs that selectively activate protein kinase A
(PKA) or the exchange protein directly activated by cAMP (EPAC)
demonstrated that regulation of NHE3 activity by exendin-4 requires
activation of both cAMP downstream effectors. This conclusion was
based on the following observations: 1) the PKA antagonist H-89
completely prevented the effect of the PKA activator but only par-
tially blocked the exendin-4-induced NHE3 inhibition; 2) the MEK1/2
inhibitor U-0126 abolished the effect of the EPAC activator but only
diminished the exendin-4-induced NHE3 inhibition; 3) combination
of H-89 and U-0126 fully prevented the effect of exendin-4 on NHE3;
4) no additive effect in the inhibition of NHE3 activity was observed
when exendin-4, PKA, and EPAC activators were used together.
Mechanistically, the inhibitory effect of exendin-4 on pHi recovery
was associated with an increase of NHE3 phosphorylation. Con-
versely, this inhibition took place without changes in the surface
expression of the transporter. We conclude that GLP-1 receptor
agonists modulate sodium homeostasis in the kidney, most likely by
affecting NHE3 activity.
dipeptidyl peptidase IV; sodium reabsorption; intracellular pH; pro-
tein kinase A; exchange protein directly activated by cAMP
NHE3 IS THE APICALLY LOCATED Na/H exchanger that mediates
the majority of NaCl and NaHCO3 reabsorption in the renal
proximal tubule (2, 42, 47, 48, 50). Numerous physiological
and humoral factors regulate NHE3 activity, thereby contrib-
uting to the fine control of fluid and electrolyte homeostasis (1,
8, 12, 40, 46, 52).
To understand the molecular mechanisms underlying regu-
lation of NHE3, there has been great interest in identifying
proteins that associate with the transporter. We previously
reported (13) that NHE3 and the serine protease dipeptidyl
peptidase IV (DPPIV) reside together as an oligomeric com-
plex in the renal proximal tubule. The functional role of DPPIV
in regulating NHE3 activity has been shown in OKP cells (a
line of opossum proximal tubule cells) (15) and in the intact
proximal tubule in vivo (14). We have demonstrated that
highly specific competitive inhibitors that bind to the active site
of DPPIV significantly reduce NHE3 function, suggesting that
the DPPIV catalytic site has a tonic role in stimulating NHE3
(14, 15).
DPPIV is a multifunctional protein expressed on the surface
of several cell types, including epithelial cells, endothelial
cells, and lymphocytes (34). It selectively cleaves NH2-termi-
nal dipeptides from proteins having proline or alanine in amino
acid position 2 (25, 34). DPPIV also acts as a binding protein
(34) and signaling molecule (29, 34).
Currently, the molecular mechanisms by which DPPIV
modulates NHE3 activity are not well understood. DPPIV is
known to degrade a variety of peptide hormones, cytokines,
and chemokines (34, 37). It is possible that DPPIV plays a
tonic role in stimulating NHE3 by processing an inhibitory
peptide involved in modulation of the transporter. The effect of
DPPIV inhibition on NHE3 activity might thereby be mediated
by increasing the half-life of this candidate peptide. One such
candidate is the DPPIV substrate glucagon-like peptide 1
(GLP-1).
GLP-1 is a hormone produced in intestinal L-type cells and
released into the bloodstream in response to ingested food (9,
23). It stimulates -cell proliferation and insulin secretion in a
glucose-dependent manner, suppresses glucagon secretion, in-
hibits gastric emptying, and reduces appetite and food intake
(4, 9, 10, 23). As a result of such biological actions, GLP-1 is
considered a potential therapeutic agent for type 2 diabetes.
However, the usefulness of native GLP-1 is limited because of
its rapid inactivation by DPPIV (7, 30). In contrast, exendin-4,
a 39-amino acid peptide that shares 53% sequence homology
with GLP-1, has a much higher in vivo half-life on account of
its NH2-terminal resistance to DPPIV cleavage (45). Exendin-4
was originally isolated from the salivary glands of the Gila
monster (Heloderma suspectum), a poisonous lizard from the
deserts of Arizona (11), and is now registered as an antidiabetic
agent under the name of Byetta (4).
The effects of GLP-1 and exendin-4 are mediated after
binding to a specific plasma membrane receptor of the G
protein-coupled receptor family (GLP-1R). The GLP-1R is
expressed not only in the pancreatic -cell but also in the brain,
the kidneys, the lungs, the pituitary gland, the heart, the
stomach, the small intestine, and major blood vessels (10, 23,
41). This widespread distribution of the GLP-1R suggests that
GLP-1 may exert a large variety of biological actions.
Animal studies indicate that GLP-1 has natriuretic and
diuretic properties (35, 39, 51), and infusion studies in humans
confirm these actions (19, 20), suggesting a potential role for
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this peptide in sodium and water homeostasis. It is noteworthy
that Gutzwiller and colleagues (20) found that intravenous
infusion of GLP-1 into healthy and insulin-resistant obese
subjects not only increases urinary sodium excretion but also
reduces urinary proton secretion, implicating a role for GLP-1
in modulation of renal Na/H exchange.
On the basis of these observations, the present study was
undertaken to evaluate the role of the GLP-1R agonist ex-
endin-4 in modulating the activity of NHE3 in the kidney
proximal tubule. We demonstrate that exendin-4 significantly
inhibits NHE3-mediated Na-dependent intracellular pH (pHi)
recovery in LLC-PK1 cells, supporting the notion that GLP-1R
agonists modulate sodium homeostasis in the kidney, most
likely by affecting NHE3 activity.
METHODS
Materials. The LLC-PK1 cell line first described by Hull et al. (28)
was obtained from the American Type Culture Collection (Manassas,
VA). Dulbecco’s modified Eagle’s medium (DMEM), heat-inacti-
vated fetal bovine serum, sodium pyruvate, and penicillin-streptomy-
cin were purchased from GIBCO Invitrogen (Grand Island, NY).
BCECF-AM was obtained from Molecular Probes (Eugene, OR).
Exendin-4, exendin-9 and GLP-1 were from Bachem (Torrance, CA).
HOE-694 and S3226 were gifts from Sanofi-Aventis (Frankfurt,
Germany). The cAMP analogs 8-(4-chlorophenylthio)-2-O-methyl-
adenosine-3,5-cyclic monophosphate (8-pCPT-2-O-Me-cAMP)
and N6-monobutyryladenosine-3,5-cyclic monophosphate (6MB-
cAMP) were from BioLog Life Science Institute (Bremen, Germany).
EZ-Link sulfo-NHS-SS-biotin as well as immunopure immobilized
streptavidin were purchased from Pierce (Rockford, IL). Rabbit poly-
clonal anti-pSer/Thr (18) was purchased from Cell Signaling Tech-
nology (Beverly, MA). The monoclonal (MAb) anti-NHE3 antibody
2B9 (2) was kindly provided by Dr. Peter Aronson and Dr. Daniel
Biemesderfer at Yale University. In a previous paper, we described
(13) the development and characterization of MAb 1D11 to rabbit
DPPIV. Horseradish peroxidase-conjugated goat anti-mouse and goat
anti-rabbit secondary antibodies were purchased from Zymed labora-
tories (San Francisco, CA). All other materials were from Sigma-
Aldrich (St. Louis, MO), if not stated otherwise.
Cell culture. Cell passages 2–10 were used in our experiments.
LLC-PK1 cells were maintained in 75-cm2 tissue culture flasks in
DMEM supplemented with 45 mM NaHCO3, 25 mM HEPES buffer,
0.1 mM sodium pyruvate, 0.01 mM nonessential amino acids, 10%
(vol/vol) heat-inactivated fetal bovine serum, 100 U/ml penicillin, and
100 g/ml streptomycin. Cultures were incubated at 37°C in a
humidified 5% CO2-air atmosphere. Cells were subcultured with
Ca2/Mg2-free phosphate-buffered saline and 0.25% trypsin-EDTA.
The medium was replaced every 2 days. For experiments, cells were
seeded onto tissue culture plates, grown to confluence, and serum
starved for 24 h before studies.
RT-PCR. Total RNA was extracted from LLC-PK1 cells with
TRIzol reagent (Invitrogen) and from rat tissues (renal cortex, renal
medulla, and pancreas) with guanidinium thiocyanate. The quality and
quantity of RNA were assessed by spectrophotometry at 260 and 280
nM. First-strand cDNA synthesis was performed with SuperScript III
reverse transcriptase according to the manufacturer’s recommended
protocols. The resulting cDNAs (50 ng each) were subjected to PCR
using the degenerated oligonucleotide primers 5-TGTACCGGT-
TCTGCACRGCTGA-3 (forward) and 5-AAGCGATGACCARS-
GCGGAGA-3 (reverse). The degenerate primers for the amplifica-
tion of GLP-1R cDNA were designed according to the conserved
sequences between porcine (GenBank accession no. CV871385) and
rat (GenBank accession no. NM_012728) genes. The expected size of
the amplified DNA band was 189 bp. The amplification conditions
consisted of initial denaturation (95°C for 5 min) followed by 30
cycles: 95°C for 30 s, 60°C for 30 s, 72°C for 1 min, with final
extension at 72°C for 10 min. PCR products were detected with
agarose gel electrophoresis.
cAMP assays. cAMP levels were measured by enzyme immuno-
assay (cAMP Direct Biotrak EIA, GE Healthcare) according to
manufacturer’s instructions. Experiments were performed in the pres-
ence of the phosphodiesterase inhibitor IBMX (1 mM).
Fluorescence microscopy measurement of pHi. NHE activity was
measured in LLC-PK1 cells as the rate of Na-dependent pHi recov-
ery after an acid load. Dual excitation ratio determinations from the
fluorescent pH-sensitive probe BCECF were used to measure pHi, as
previously detailed (5). Briefly, cells were grown to confluence on
glass slides, placed into a thermoregulated chamber, and mounted on
an inverted epifluorescence microscope (Nikon, TMD). Next, they
were loaded with 10 M BCECF acetoxymethyl ester in Ringer
solution (solution 1, Table 1) for 10 min. The acetoxymethyl ester
form of BCECF enters the cell and is rapidly converted to the
anionic-free acid form by intracellular esterases. After the loading
period, the glass coverslips were rinsed with the control solution to
remove the BCECF-containing solution for a few minutes and pre-
pulsed with 20 mM NH4Cl in HEPES-buffered control solution
(solution 3, Table 1) at 37°C for subsequent acid loading. Fluores-
cence was measured by using 440 (pH insensitive) or 495 (pH
sensitive) nm alternately as excitation wavelengths utilizing a xenon
light source. Emission was measured at 530 nm by a photomultiplier-
based fluorescence system (Georgia Instruments, PMT-4000) at time
intervals of 5 s. pHi was calibrated by equilibrating the cells with
high-K medium (solution 2, Table 1) titrated to defined pH values
and containing 10 g/ml nigericin.
Cell pH recovery. Cell pH recovery was examined after the
acidification of pHi with the NH4Cl pulse technique after 2-min
exposure to 20 mM NH4Cl (solution 3, Table 1) in the presence of
external 145 mM Na (solution 1, Table 1). In all experiments, we
calculated the initial rate of pH recovery (dpH/dt, pH units/min) from
the first 2 min after the start of the pHi recovery curve by linear
regression analysis.
Measurement of intracellular buffering capacity. In our system,
intracellular buffering capacity (i) corresponds to the sum of the
individual buffering powers of all cytosolic buffers, excluding HCO3/
CO2. Hence, estimations of i were performed with HEPES-buffered
solutions. i was determined with the technique described by Boy-
arsky et al. (3) and calculated as described by Weintraub and Machen
(49). The H membrane transporters were blocked by a Na-free
solution plus 0.1 M concanamycin. After removal of Na from the
external medium, the cells were exposed to a HEPES-buffered solu-
tion containing 50 mM NH4Cl, which was then stepwise reduced to 1
mM (in 50, 20, 10, 5, 2.5, and 1 mM steps). Calculation of i was
Table 1. Composition of solutions
Solution 1 Solution 2 Solution 3
Reagents Ringer 1K Medium NH4Cl
NaCl 141.0 20.0 121.0
KCl 5.4 130.0 5.4
CaCl2 1.0 1.0 1.0
KH2PO4 0.4 0.4
MgCl2 0.5 1.0 0.5
MgSO4 0.4 0.4
Na2HPO4 0.3 0.3
HEPES 10.0 5.0 10.0
Glucose 0.6 0.6
NH4Cl 20.0
pH 7.4 6, 7, and 8 7.4
All values are in mM, except for pH. NMDG, N-methyl-D-glucamine. HCl
or NaOH was used in all Na-containing solutions to titrate to the appropriate
pH, and KOH was used in the Na-free solution.
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performed according to the formula i  [NH4]i/pHi, where the
intracellular NH4 concentration ([NH4]i) was calculated from the
Henderson-Hasselbalch equation on the assumption that NH3i NH3.
Immunoprecipitation. LLC-PK1 cells grown in six-well plates were
solubilized at 4°C in a modified RIPA buffer containing 150 mM
NaCl, 5 mM EDTA, 1% (vol/vol) Triton X-100, 0.5% (wt/vol)
deoxycholate, 50 mM Tris HCl, pH 7.4, supplemented with protease
inhibitors (0.7 g/ml pepstatin A, 0.5 g/ml leupeptin, and 40 g/ml
PMSF) and phosphatase inhibitors (50 mM NaF and 15 mM sodium
pyrophosphate). The samples were subjected to centrifugation (14,000
g for 10 min) with a table top centrifuge (Eppendorf model 5402R).
Fifty micrograms of primary antibodies was added to the supernatants,
and the samples were incubated at 4°C for 1 h. Immune complexes
were collected with 5 mg/sample of protein G-Sepharose 4B (GE
Healthcare). The beads were washed five times in modified RIPA
buffer and then prepared for SDS-PAGE and immunoblotting.
Cell surface biotinylation. The assay was performed as described
previously (15). Cells were rinsed twice in ice-cold PBS-Ca-Mg (PBS
with 0.1 mM CaCl2, 1.0 mM MgCl2). Surface membrane proteins
were then biotinylated by incubating the cells twice for 25 min with
2 ml of ice-cold biotinylation buffer (150 mM NaCl, 10 mM trieth-
anolamine, 2 mM CaCl2, and 2 mg/ml EZ-Link sulfo-NHS-SS-
biotin). Cells were then rinsed twice for 20 min with a quenching
buffer (PBS-Ca-Mg, 100 mM glycine), washed twice with ice-cold
PBS-Ca-Mg, and scraped into ice-cold solubilization buffer (50 mM
Tris, 150 mM NaCl, 1 mM EDTA, 0.5% sodium deoxycholate, 1%
Triton X-100, pH 7.4) containing protease inhibitors (0.7 g/ml
pepstatin A, 0.5 g/ml leupeptin, and 40 g/ml PMSF). After lysis on
ice for 60 min, extracts were centrifuged for 10 min at 14,000 g and
4°C. The protein concentration of the supernatants was measured (36),
and equal protein amounts of cell lysate (500 g) were equilibrated
with streptavidin-agarose beads at 4°C. The beads were then washed
five times in ice-cold solubilization buffer. Biotinylated proteins were
released by incubation in Laemmli buffer and subjected to SDS-
PAGE and immunoblotting.
SDS-PAGE and immunoblotting. Proteins were solubilized in sam-
ple buffer (2% SDS, 20% glycerol, 100 mM dithiothreitol, 50 mM
Tris pH 6.8, 0.05% bromophenol blue) and separated by SDS-PAGE
using 7.5% polyacrylamide gels. Proteins were then transferred from
the polyacrylamide gel to a polyvinylidene difluoride (PVDF) micro-
porous membrane (Immobilon-P; Millipore, Bedford, MA) that was
used for immunoblotting. The PVDF membrane was incubated with
blocking solution [5% nonfat dry milk and 0.1% Tween 20 in PBS,
pH 7.4 or 5% albumin and 0.1% Tween 20 in Tris-buffered saline
(TBS) buffer, pH 7.4, when probing with anti-pSer/Thr antibody] for
1 h at room temperature to block nonspecific binding, followed by
overnight incubation at 4°C with the primary antibody in blocking
solution. The membranes were then washed five times in blocking
solution and incubated for 1 h with horseradish peroxidase-conjugated
IgG secondary antibodies from Zymed Laboratories (1:2,000). Mem-
branes were again washed with blocking solution and then rinsed with
PBS or TBS. Bound antibody was detected with enhanced chemilu-
minescence (ECL) (GE Healthcare, Piscataway, NJ) according to
manufacturer’s protocols. Multiple exposures of Kodak BioMax MR
Film (Kodak, Rochester, NY) were made to ensure that signals were
within the linear range of the film. The visualized bands were digitized
with the ImageScanner (GE Healthcare) and quantified with Scion
Image Software (Scion, Frederick, MD).
Statistics. All results are reported as means 	 SE, with n indicating
the number of observations. Comparisons between two groups were
performed with unpaired t-tests. If more than two groups were
compared, statistical significance was determined by ANOVA fol-
lowed by Tukey’s post hoc test. A P value 
0.05 was considered
significant. The Graph Pad Prism 4 program (Graph Pad Software,
San Diego, CA) was used to calculate significance.
RESULTS
Expression of glucagon-like peptide 1 receptor in LLC-PK1
cells. Expression of mRNA encoding GLP-1R was examined
by means of RT-PCR and DNA sequencing analyses. GLP-1R
mRNA was expressed in LLC-PK1 cells and rat renal cortex;
rat pancreas cDNA was used as positive control. In contrast,
GLP-1R message was not detected in the rat renal medulla
(Fig. 1A).
The GLP-1R is a G protein-coupled receptor whose activa-
tion by ligands stimulates the formation of intracellular cAMP
(10, 16, 17). As shown in Fig. 1B, LLC-PK1 cell treatment with
1 nM exendin-4 for 30 min significantly increased the intra-
cellular levels of cAMP. The GLP-1R antagonist exendin-9
(16, 43) alone did not alter intracellular cAMP production but
Fig. 1. Functional expression of glucagon-like peptide 1 receptor (GLP-1R) in
LLC-PK1 cells. A: RT-PCR detection of GLP-1R in rat pancreas, rat renal
cortex, rat renal medulla, and LLC-PK1 cells. Total RNA was extracted from
rat tissues and LLC-PK1, reverse transcribed, and amplified by PCR as
described in METHODS. After PCR amplification, a single band with the
predicted size (189 bp) was clearly detected in rat islets, rat renal cortex, and
LLC-PK1 cDNAs. B: effects of exendin-4 (Ex-4; 1 nM), exendin-9 (Ex-9; 1
M), and combination of exendin-4 with exendin-9 on generation of intracel-
lular cAMP in LLC-PK1 cells. Cells were treated with the above-mentioned
drugs for 30 min at 37°C. cAMP levels were measured by enzyme immuno-
assay (cAMP Direct Biotrak EIA, GE Healthcare) according to manufacturer’s
instructions. Each assay was performed in triplicate, and the mean values of 5
assays were calculated. *P 
 0.001 vs. control (Ctrl).
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completely inhibited the effect of exendin-4. No additive effect
on cAMP levels was observed when LLC-PK1 cells were
treated with a combination of GLP-1 and exendin-4 compared
with cells treated with exendin-4 alone. These results strongly
suggest that exendin-4 functionally interacts with its receptor
in LLC-PK1 cells.
Modulation of NHE3 activity by exendin-4 in LLC-PK1 cells.
To determine whether exendin-4 modulates NHE3 activity, we
examined the effect of this peptide on Na-dependent pHi
recovery from an acid load in LLC-PK1 cells by using the
NH4Cl pulse technique. Representative tracings of pHi changes
in LLC-PK1 cells treated with vehicle or exendin-4 are shown
in Fig. 2, A and B, respectively. LLC-PK1 cells were acidified
to a pHi of 6.4, and the rates of pHi recovery were deter-
mined in the presence of external Na. As shown in Fig. 2C,
the Na-dependent pHi recovery rates were significantly
slower in exendin-4-treated cells (0.34 	 0.02 pH units/min)
than in controls (0.53 	 0.07 pH units/min). We also deter-
mined the H buffering power in LLC-PK1 cells treated or not
with exendin-4 to rule out that the effect of this peptide on
dpH/dt was due to alterations in the intracellular intrinsic
buffering capacity i. i was estimated over the range 6.3–7.0
with stepwise reduction of external NH4Cl. The resulting
estimates of i at various values of pHi are illustrated in Fig.
2D. Our data revealed no difference in i between control and
exendin-4-treated LLC-PK1 cells.
Because LLC-PK1 cells express both NHE1 and NHE3
isoforms, we next sought to examine whether the decreased
Na-dependent pHi recovery induced by exendin-4 was due to
inhibition of NHE1 and/or NHE3 activity. For this purpose,
experiments were performed with 10 M HOE-694 and 10 M
S3226, to inhibit selectively NHE-1 and NHE-3 isoforms,
respectively. As seen in Fig. 3, HOE-694 inhibited 50% of
total Na-dependent pHi recovery in LLC-PK1 cells (0.24 	
0.02 pH units/min). The HOE-694-insensitive rate of pHi
recovery could be reduced still more by exendin-4 (0.11 	
0.01 pH units/min). Conversely, no difference was found
Fig. 2. Exendin-4 inhibits Na-dependent intra-
cellular pH (pHi) recovery in LLC-PK1 cells.
LLC-PK1 cells grown to confluence on glass cov-
erslips were loaded with NH4Cl (20 mM) in a
HEPES-buffered solution containing vehicle
(Ctrl) or 1 nM exendin-4. After 30 min, cells were
transferred to a similar medium devoid of NH4Cl
(pH 7.4). A and B: representative tracings illus-
trating pHi changes in control (A) and exendin-4-
treated (B) LLC-PK1 cells. C: initial rate of pH
recovery (dpH/dt, pH units/min; first 2 min) was
calculated from curves of control and exendin-4-
treated cells by linear regression analysis. n 
6/group. *P
 0.001 vs. Ctrl. D: estimated intrin-
sic buffering power plotted as a function of pHi in
LLC-PK1 cells treated with vehicle or exendin-4.
Fig. 3. Exendin-4 inhibits Na/H exchanger (NHE)3-mediated Na-depen-
dent pHi recovery in LLC-PK1 cells. LLC-PK1 cells grown to confluence on
glass coverslips were treated for 30 min with vehicle (Ctrl) or 1 nM exendin-4
in the presence or absence of specific NHE isoform inhibitors. Initial rate of
Na-dependent pHi recovery after cellular acidification with the NH4Cl pulse
technique was measured as described in METHODS. Number of experiments is
indicated in bars. *P 
 0.001 vs. Ctrl; #P 
 0.05 vs. HOE-694.
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between cells exposed to S3226 in the presence (0.26 	 0.03
pH units/min) or absence (0.21 	 0.02 pH units/min) of
exendin-4, suggesting that the HOE-694-sensitive S3226-resis-
tant NHE1 isoform is not modulated by exendin-4.
Together these findings provide strong evidence that ex-
endin-4 decreases Na-dependent pHi recovery rates from cell
acidification in LLC-PK1 cells by inhibiting NHE3-mediated
Na/H exchange activity.
In all subsequent functional studies, 10 M HOE-694 was
used to inhibit NHE1.
Role of cAMP signaling pathway in regulation of NHE3 by
exendin-4 in LLC-PK1 cells. As noted above, exposure of
LLC-PK1 cells to 1 nM exendin-4 leads to significant increases
in intracellular cAMP. We therefore examined whether the
effect of exendin-4 on NHE3 in kidney proximal tubule cells
depends on components of the cAMP signaling pathway. The
data presented in Fig. 4 show that the membrane-permeant
cAMP analog 8-bromoadenosine 3,5-cyclic monophosphate
(8-BrcAMP; 100 M) caused a decrement in the initial rates of
Na-dependent pHi recovery very similar in magnitude to that
caused by exendin-4 (0.12 	 0.02 vs. 0.11 	 0.02 pH units/
min). Furthermore, the effects of exendin-4 and 8-BrcAMP
were not additive (0.12 	 0.03 pH units/min).
As intracellular cAMP accumulates and subsequently in-
creases protein kinase A (PKA) activity, we further addressed
the involvement of this kinase in the exendin-4-mediated
NHE3 inhibition in LLC-PK1 cells. As summarized in Fig. 5,
pretreatment with the PKA inhibitor H-89 (1 M) had no
intrinsic effects on pHi responses (0.28 	 0.02 vs. 0.25 	 0.02
pH units/min) but fully prevented the inhibitory effect of the
PKA activator 6MB-cAMP (0.25 	 0.03 vs. 0.13 	 0.02 pH
units/min). Alternatively, H-89 significantly but not com-
pletely blocked the inhibitory effect of exendin-4 on NHE3-
mediated pHi recovery in LLC-PK1 cells (0.19 	 0.01 vs.
0.11 	 0.03 pH units/min; P 
 0.01), strongly suggesting that
an additional mechanism is involved in modulation of NHE3
by exendin-4.
Exchange protein directly activated by cAMP (EPAC) is a
recently discovered cAMP sensor that mediates intracellular
cAMP actions in addition to the classic PKA cascade (6). Data
from the literature demonstrated that EPAC mediates the
cAMP-dependent guanine nucleotide exchange that activates
Rap-1 (6). Activation of Rap-1 stimulates the kinase activity of
B-Raf and the phosphorylation of mitogen-activated protein
kinases MEK1/2 that subsequently phosphorylates and acti-
vates ERK1/2 (26). Since there are no available EPAC antag-
onists, the contribution of this pathway to the exendin-4-
induced NHE3 inhibition was examined by using a cAMP
analog that specifically activates EPAC (8-pCPT-2-O-Me-
cAMP) and the compound U-0126, an inhibitor of its down-
stream effector MEK1/2 kinase. As depicted in Fig. 6A, EPAC
stimulation decreased NHE3-dependent pHi recovery in LLC-
PK1 cells (0.13 	 0.01 pH units/min). Preincubation for 30
min with U-0126 (50 M) had no intrinsic effects on pHi
compared with control (0.26 	 0.01 vs. 0.25 	 0.02 pH
units/min) but totally prevented the inhibitory effect of EPAC
on NHE3 activity (0.25 	 0.03 vs. 0.13 	 0.01 pH units/min).
In contrast, U-0126 curtailed but did not abolish the exendin-4
effect (0.20 	 0.01 pH units/min). Since MEK1/2 may also be
activated by PKA, we tested whether U-0126 would prevent
the effect of PKA activation on NHE3 activity. A tendency to
decrease the NHE3 inhibition generated by PKA was noted in
the presence of U-0126, but it did not reach statistical signif-
icance (data not shown).
Further evidence implicating both PKA and EPAC pathways
in mediating the exendin-4-induced inhibition of NHE3 is
provided in Fig. 6B. The pretreatment of LLC-PK1 with both
H-89 and U-0126 abolished the exendin-4 effect. Additionally,
no synergistic effect on the reduction of NHE3 activity is
observed when LLC-PK1 cells are treated simultaneously with
exendin-4 and the cAMP analogs that selectively activate PKA
or EPAC.
Fig. 4. cAMP mediates exendin-4-induced NHE3 inhibition in LLC-PK1 cells.
LLC-PK1 cells grown to confluence on glass coverslips were incubated with 1
nM exendin-4, 100 M 8-bromoadenosine 3,5-cyclic monophosphate (8-
BrcAMP), 1 nM exendin-4  100 M 8-BrcAMP, or vehicle. The HOE-694-
insensitive component of Na-dependent pHi recovery was measured in
LLC-PK1 cells by the NH4Cl pulse technique. Number of experiments is
indicated in bars. *P 
 0.001 vs. Ctrl.
Fig. 5. Inhibitory effect of exendin-4 on NHE3 in LLC-PK1 cells is partially
mediated by protein kinase A (PKA). Confluent LLC-PK1 cells were preincu-
bated or not with the PKA inhibitor H-89 (1 M) for 30 min before and during
treatment with 1 nM exendin-4, 100 M 8-BrcAMP, 50 M PKA activator, or
vehicle. The HOE-694-insensitive component of Na-dependent pHi recovery
was measured in LLC-PK1 cells by the NH4Cl pulse technique. Number of
experiments is indicated in bars. *P
 0.001 vs. Ctrl; #P
 0.05 vs. Ctrl; †P

0.01 vs. exendin-4.
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Collectively, these findings suggest that regulation of NHE3
activity in LLC-PK1 cells by the GLP-1R agonist exendin-4
occurs through both PKA- and EPAC-dependent mechanisms.
Molecular mechanisms underlying acute regulation of
NHE3 by exendin-4. Several studies have shown that cAMP-
dependent PKA phosphorylates COOH-terminal NHE3 (27,
31–33, 38, 53). We therefore examined whether PKA activa-
tion induced by exendin-4 led to increased NHE3 phosphory-
lation. To this end, LLC-PK1 cells were pretreated or not with
the PKA inhibitor H-89, followed by addition of exendin-4,
8-BrcAMP, or vehicle. Cells were solubilized, and the result-
ing supernatant was immunoprecipitated with an antibody
directed to NHE3 (MAb 2B9). The levels of NHE3 phosphor-
ylation were then analyzed by immunoblotting using an anti-
pSer/Thr antibody (18). As shown in Fig. 7, exendin-4,
8-BrcAMP, and the PKA activator 6MB-cAMP induced a
significant increase of NHE3 phosphorylation levels [123 	
9% (n  6), 160 	 25% (n  6), and 144 	 23% (n  3),
respectively] compared with control. As expected, pretreat-
ment with H-89 completely prevented increases of NHE3
phosphorylation induced by these agents.
Consistent with previous findings (27), Kocinsky and co-
workers (31) recently reported that phosphorylation of NHE3
at PKA consensus sites precedes transport inhibition, suggest-
ing that phosphorylation per se is not sufficient to inhibit NHE3
activity. The authors postulated that PKA phosphorylation may
subsequently result in NHE3 inhibition by altering NHE3
subcellular trafficking and/or modulating the interaction with
regulatory proteins (31). To investigate whether the effect of
exendin-4 to reduce NHE3 activity is due to changes in NHE3
surface expression, we performed cell surface biotinylation.
The biotinylated surface proteins were precipitated on strepta-
Fig. 7. Exendin-4 increases phosphorylation of NHE3 in LLC-PK1 cells.
A: Confluent LLC-PK1 cells were preincubated or not with the PKA inhibitor
H-89 (1 M) for 30 min before and during treatment with 1 nM exendin-4, 100
M 8-BrcAMP, 50 M PKA activator, or vehicle. Solubilized LLC-PK1
protein extracts (500 g) were then immunoprecipitated (IP) with anti-NHE3.
Immune complexes were prepared for immunoblotting (IB) and probed with an
anti-pSer/Thr antibody. The blot was then stripped and probed with anti-NHE3
to show that equal amounts of NHE3 were immunoprecipitated in each lane.
B: relative abundance of phosphorylated NHE3 was quantitated by densitom-
etry and the combined data from 3 experiments are represented. *P
 0.001 vs.
Ctrl.
Fig. 6. Exendin-4-induced NHE3 inhibition in LLC-PK1 cells occurs through
both PKA- and exchange protein directly activated by cAMP (EPAC)-depen-
dent mechanisms. A: confluent LLC-PK1 cells were preincubated or not with
the MEK1/2 inhibitor U-0126 (50 M) for 30 min before and during treatment
with 1 nM exendin-4, 50 M EPAC activator, or vehicle. B: confluent
LLC-PK1 cells were preincubated or not with the PKA inhibitor H-89 (1 M)
and with the MEK1/2 inhibitor U-0126 (50 M) for 30 min before and during
treatment with 1 nM exendin-4. Another series of experiments were performed
by treating cells with 1 nM exendin-4, 50 M PKA activator, and 50 M
EPAC activator. The HOE-694-insensitive component of Na-dependent pHi
recovery was measured in LLC-PK1 cells by the NH4Cl pulse technique.
Number of experiments is indicated in bars. *P 
 0.001 vs. Ctrl; #P 
 0.001
vs. Ex-4.
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vidin followed by immunoblotting analysis of NHE3. As
shown in Fig. 8, exendin-4 had no significant effect on NHE3
surface expression in LLC-PK1 cells.
We next tested whether increases of NHE3 phosphorylation
induced by exendin-4 would affect the stability of the NHE3-
DPPIV complex. To this end, LLC-PK1 cells incubated in the
presence of exendin-4 or vehicle were solubilized and the
resulting supernatant was immunoprecipitated with anti-DPPIV
(MAb 1D11). The immune complexes were analyzed for the
presence of NHE3 by immunoblotting. As seen in Fig. 9,
exendin-4 treatment did not alter the amount of NHE3 in the
DPPIV immune complex.
On the basis of these results, we conclude that acute treat-
ment of LLC-PK1 cells with exendin-4 increases NHE3 phos-
phorylation levels. The inhibitory effect of exendin-4 on NHE3
function is not associated with changes of NHE3 surface
expression and occurs without affecting the assembly between
NHE3 and DPPIV.
DISCUSSION
The potential role of GLP-1 and exendin-4 in modulating
salt and water homeostasis has recently been reported in a
series of elegant studies (19, 20, 22, 35, 39, 51). However, the
assumption that GLP-1 reduces renal sodium reabsorption by
affecting NHE3 activity is mainly based on indirect evidence.
In the present study we demonstrate for the first time that the
GLP-1R agonist exendin-4 inhibits NHE3-mediated Na/H
exchange in renal proximal tubule cells. Additionally, our data
suggest that binding of exendin-4 to GLP-1R in LLC-PK1 cells
endogenously activates two cAMP downstream effectors, PKA
and EPAC.
The role of EPAC in regulation of NHE3 activity has been
recently shown by Honegger and colleagues (24). However,
the mechanism by which EPAC activation leads to NHE3
inhibition is still elusive. Here we demonstrate that LLC-PK1
cell pretreatment with the MEK1/2 inhibitor U-0126 abolished
the effect of the EPAC activator and diminished the exendin-
4-induced NHE3 inhibition. Unexpectedly, neither exendin-4
nor EPAC activation changed the phosphorylation status of the
MEK1/2 substrate ERK1/2 in LLC-PK1 cells (data not shown).
One possible way to reconcile these findings is by postulating
that the effect of EPAC on NHE3 involves phosphorylation of
a still unidentified protein by MEK1/2.
Biochemical and physiology studies have established the
important role of PKA phosphorylation in regulating NHE3
activity (27, 31–33, 38, 53). Nonetheless, there is evidence
from both in vitro (27) and in vivo (31) studies that phosphor-
ylation per se is insufficient to inhibit NHE3. In the present
report, we found that exendin-4 increases NHE3 phosphoryla-
tion without affecting NHE3 surface expression or its associ-
ation with DPPIV. The subsequent events that lead to NHE3
inhibition may involve the association of NHE3 with other
binding partners or yet unidentified mechanisms.
Fig. 8. Exendin-4 does not change NHE3 surface expression in LLC-PK1
cells. A: confluent LLC-PK1 cells were treated for 30 min with vehicle (Ctrl)
or 1 nM exendin-4. Cell surface biotinylated proteins were subjected to
SDS-PAGE and immunoblotting. Western blot analyses were performed with
a monoclonal antibody against NHE3. B: abundance of NHE3 antigen was
quantitated by densitometry, and the combined data from 4 experiments are
represented.
Fig. 9. Exendin-4 does not affect the stability of the NHE3-dipeptidyl pepti-
dase IV (DPPIV) complex in LLC-PK1 cells. Confluent LLC-PK1 cells were
treated with 1 nM exendin-4 or vehicle for 30 min. Equivalent quantities (500
g) of solubilized LLC-PK1 cells were immunoprecipitated with an anti-
DPPIV antibody. All incubation and washing solutions contained 1 nM
exendin-4. A: immune complexes were prepared for immunoblotting, and the
blot was probed with a monoclonal antibody directed to NHE3. To determine
loading the blot was stripped and reprobed with an anti-DPPIV antibody.
B: relative abundance of the NHE3-DPPIV complex was quantitated by
densitometry, and the combined data from 3 experiments are represented.
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Our earlier studies demonstrated that NHE3 and DPPIV
reside together in multimeric complexes in the renal brush-
border membrane (13) and that specific competitive inhibitors
that bind to the active site of DPPIV significantly reduce
NHE3-mediated NaHCO3 reabsorption in the rat renal proxi-
mal tubule (14). On the basis of our present and previous
observations, we propose the following model to explain the
role of GLP-1 in mediating the functional interaction between
NHE3 and DPPIV in the intact proximal tubule in vivo.
Inhibition of DPPIV activity by specific competitive inhibitors
increases the levels of GLP-1 in the bloodstream and conse-
quently in the glomerular ultrafiltrate. In the renal proximal
tubule, GLP-1 binds to its receptor GLP-1R, increasing the
intracellular levels of cAMP, leading, in turn, to cAMP-
dependent activation of the PKA and EPAC pathways. Subse-
quent inhibition of NHE3-mediated Na/H exchange in prox-
imal tubule decreases sodium, bicarbonate, and water reabsorp-
tion. This hypothetical model is consistent with human studies
in which GLP-1 infusions enhanced urinary sodium excretion
and decreased proton secretion in healthy volunteers and in
patients with type 2 diabetes (20).
The association of NHE3 with DPPIV, and the fact that this
peptidase processes the peptide GLP-1 that is involved in
regulation of the transporter, raises the possibility that NHE3,
DPPIV, and the GLP-1R are linked together to form a func-
tional unit. Of note, Herrera and coworkers (21) have reported
that DPPIV interacts with the chemokine receptor CXCR4 in
lymphocytes, in which the DPPIV-CXCR4 complex seems to
play a role in immune system function and the pathophysiology
of human immunodeficiency virus (HIV) infection. Binding of
the CXCR4 ligand stromal cell-derived factor 1- (SDF-1) to
its receptor results in cointernalization of CXCR4 and DPPIV.
SDF-1 is a substrate of DPPIV, and when this peptidase is
expressed on the cell surface SDF-1 is cleaved and inacti-
vated (39). The association between DPPIV and CXCR4 illus-
trates a regulatory mechanism that implicates both catalytic
and binding properties of DPPIV. By analogy, it is possible
that NHE3, DPPIV, and the GLP-1R physically and function-
ally interact in the renal brush-border membrane to regulate
salt and water homeostasis. Unfortunately, we were unable to
investigate whether a physical interaction between these pro-
teins exists in LLC-PK1 because specific GLP-1R antibodies
suitable for immunoprecipitation and/or immunoblotting in
LLC-PK1 cells are not available.
In summary, we have found that the GLP-1R agonist ex-
endin-4 reduces NHE3 activity in renal proximal tubule cells.
This effect is mediated via PKA and EPAC signaling pathways
and is associated with increased levels of NHE3 phosphoryla-
tion. The inhibition of DPPIV may enhance the renal effects of
GLP-1, and might explain why DPPIV inhibitors decrease
NHE3-mediated NaHCO3 reabsorption in the rat renal proxi-
mal tubule.
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